Vertex Strikes Deal to Purchase Alpine Immune Sciences
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, today announced that the companies have entered into a definitive…
World Health Organization Raises Concern Over Viral Hepatitis: 3,500 Lives Lost Daily
The latest Global Hepatitis Report by the World Health Organization (WHO) for 2024 reveals a concerning rise in deaths attributed to viral hepatitis. This disease now stands as the second…
WHO to Release New Guidelines for Simultaneous Treatment of Drug-Resistant Tuberculosis and Hepatitis C
In a recent announcement, the World Health Organization (WHO) has provided updates regarding the simultaneous treatment of drug-resistant tuberculosis (TB) and hepatitis C (HCV). The latest evidence suggests that administering…
Teva’s First Quarter 2024 Financial Results Conference Call Scheduled for May 8th at 8 a.m. ET
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has announced its plans to unveil the financial results for the first quarter of 2024 on Wednesday, May 8, 2024, at 7:00…
Pfizer Reveals Encouraging Phase 3 Findings of ABRYSVO® in High-Risk Adults (Ages 18-59) Vulnerable to RSV Disease
Pfizer Inc. (NYSE: PFE) has reported promising top-line data on the immunogenicity and safety of ABRYSVO® from its pivotal Phase 3 clinical trial MONeT (RSV IMmunizatiON Study for AdulTs at…
SkinMedica® Revolutionizes Acne Care for Clear Skin Confidence
Allergan Aesthetics, a subsidiary of AbbVie Inc. (NYSE: ABBV), has unveiled two new additions to the SkinMedica® lineup, developed by the creators of BOTOX® Cosmetic. These groundbreaking products, the SkinMedica®…
BridgeBio Pharma: CMR Imaging Supports Clinical Improvement in ATTR-CM Trial
BridgeBio Pharma, Inc. (Nasdaq: BBIO), a leading biopharmaceutical company specializing in genetic diseases and cancers, unveiled findings from the exploratory CMR imaging substudy of its Phase 3 trial, ATTRibute-CM, evaluating…
Ionis Reveals Encouraging Findings from Phase 3 Balance Trial of Olezarsen in Familial Chylomicronemia Syndrome
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) has unveiled comprehensive findings from the Phase 3 Balance study of olezarsen, its leading independent investigational medication, targeted at adults grappling with familial chylomicronemia syndrome…
Al-Shifa Hospital Reduced to Ruins After Six Months of War, Finds WHO Mission
A joint mission led by the World Health Organization (WHO) and several other agencies visited Al-Shifa Hospital in north Gaza on April 5 to assess the damage caused by the…
Teva’s Latest Pharmacokinetic Modeling Data Shows UZEDY® Benefits for Schizophrenia Patients at SIRS 2024
Teva Pharmaceuticals Unveils Promising PK Modeling Data and Clinical Insights at SIRS 2024 At the Schizophrenia International Research Society (SIRS) 2024 Congress, Teva Pharmaceuticals, a leading U.S. affiliate of Teva…
Positive Findings: Zilebesiran Combined with Antihypertensives for Uncontrolled Hypertension
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) has unveiled promising outcomes from the KARDIA-2 Phase 2 investigation, evaluating the effectiveness and safety of zilebesiran when combined with one of three standard antihypertensive…
Study: mRNA Immunotherapy Shows Long-Term Immune Response and Delayed Tumor Return in Pancreatic Cancer Patients
BioNTech SE (Nasdaq: BNTX) has released promising findings from a Phase 1 trial involving the mRNA-based individualized neoantigen-specific immunotherapy (iNeST) candidate autogene cevumeran (also known as BNT122, RO7198457) for patients…